tbuckley/cabot-search huggingface dataset:
SP0031 Are illness perception and coping style associated with patient delay?
Authors: K. Van der Elst
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> EULAR recommendations for rheumatoid arthritis (RA) management advocate early intensive treatment to target. Timely diagnosis and treatment initiation in RA depends on a multitude of factors, such as healthcare organisation and referral pathways. Nevertheless, individuals seem to have a large contribution themselves by delaying their first contact with a health professional after symptom onset. This pre-diagnosis period can be described as a daunting period for persons who are later diagnosed with RA, because of experiencing symptoms they do not fully understand yet. It has been shown that when confronted with particular new symptoms, persons develop or adjust certain beliefs and attitudes that determine their understanding of, and their way of dealing with these unknown symptoms. Consequently, how persons interpret (perception) and manage (coping) their initial RA-related symptoms could influence their help-seeking behaviour. The results presented in this lecture will introduce the role of illness perception and coping in the patient delay in recently diagnosed patients with early RA. The audience will learn about the role of psychosocial aspects in patients' help-seeking behaviour, and why such aspects are worthwhile to consider when aiming for a reduction in early RA treatment delay. <h3>Reference</h3> [1] Van der Elst K, et al. Are illness perception and coping style associated with the delay between symptom onset and the first general practitioner consultation in early rheumatoid arthritis management? An exploratory study within the CareRA trial. Scand J Rheumatol2016;45(3):171–8. <h3>Disclosure of Interest</h3> None declared
Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Authors: Justin Watts, Maria R. Baer, Jay Yang, Shira Dinner, Sangmin Lee, Karen Seiter, Thomas Prebet, Gary J. Schiller, Paul Brent Ferrell, Kim-Hien Dao, Hagop M. Kantarjian, Patrick Kelly, Ping Li, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, Jorge E. Cortes
Journal: Blood (2018)
SAT0107 Sequential ultrasound shows a late increase in inflammatory burden in anti-ccp positive patients with non-specific musculoskeletal symptoms just before progression to inflammatory arthritis.
Authors: P. Pentony, K. Mankia, E. M. Hensor, J. L. Nam, L. Hunt, L. Garcia-Montoya, L. Duquenne, P. Emery
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> US abnormalities occur in patients with new rheumatoid arthritis (RA) and can also predict the development of clinical synovitis in anti-CCP positive patients with musculoskeletal symptoms (MSK) (CCP+) [1]. However, the timing of development of US synovitis in relation to clinical synovitis has not been longitudinally studied. <h3>Objectives</h3> To investigate whether US synovitis (grey scale (GS) and power doppler (PD)) changes in the period prior to the development of inflammatory arthritis (IA) in CCP+ individuals compared to those who do not develop IA. <h3>Methods</h3> CCP+ individuals were prospectively followed until the development of clinical synovitis in at least one joint (progressors). Progressors were compared to CCP+ individuals who did not develop clinical synovitis (non-progressors). For all subjects, US scans were performed at baseline, 6 and 12 months and then annually, and/or at the time of onset of clinical synovitis. A 22 paired joint US score was calculated for PD and GS &gt;1 using the wrists, MCPJs (1-5) and PIPJs (1-5). Comparisons were made between baseline, the ultrasound prior to progression (or time equivalent in non-progressors)(scan 2) and progression scan (or time-equivalent) (scan 3). <h3>Results</h3> Patients with at least 3 serial US were included: 22 CCP+ progressors and 22 CCP+ non progressors. Age and gender was similar between groups. The majority of patients in both groups showed no change in PD or GS&gt;1 between baseline and scan 2 (table 1). All 22 non-progressors (100%) had a PD score of 0 at baseline, compared with 16/22 (72.7%) progressors. In contrast, between scan 2 and 3 (progression scan), the majority of patients in the progressor group increased total PD and GS scores, while non-progressors remained the same (table 1). Time between scan 2 and 3 was similar between groups. <h3>Conclusions</h3> After a period of stability the burden of US inflammation in CCP+ patients that progress to IA increases directly before the development of IA. This later increase in US inflammation may reflect a second hit in these at risk patients occurring prior to progression to IA. This may suggest that an intervention aiming to prevent the development of IA should target the subclinical phase prior to an escalation in US inflammation. <h3>Reference:</h3> [1] Nam JL, et al. Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. Ann Rheum Dis 2016;75(12):2060-2067. <h3>Disclosure of Interest:</h3> None declared
Serum Creatinine Levels Before, During, and After Pregnancy
Authors: Ziv Harel, Eric McArthur, Michelle Hladunewich, Jade S. Dirk, Ron Wald, Amit X. Garg, Joel G. Ray
Journal: JAMA (2019)

Serum Creatinine Levels Before, During, and After PregnancyEstimating renal function before and during pregnancy has clinical importance: kidney dysfunction can affect maternal and perinatal health.Glomerular hyperfiltration is a typical physiological adaptation to pregnancy, reflected by a decrease in levels of serum creatinine (SCr) with advancing gestational age.Creatinine-based equations used to estimate glomerular filtration may misclassify renal function during pregnancy, 1 as they depend on a steady state of creatinine balance.Moreover, a 24-hour collection of urine to measure cre-atinine clearance is impractical. 2Accordingly, physicians typically rely on SCr level.Previous studies attempted to define a normal SCr level in pregnancy, but they had few participants and may have been confounded by sampling bias. 3,4The current study was undertaken to generate gestational age-specific estimates of renal function-before, during, and after pregnancy-among women without antecedent kidney disease.
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)
Authors: Frank G. Rücker, Ling Du, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Michelle Geddes, Jorge Sierra, Eva Tiecke, Celine Pallaud, Miguel A. Sanz, Theo M de Witte, Dietger Niederwieser, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede, Konstanze Dohner
Journal: Blood (2018)
Telomerase activity analysis in human cell lines using a real-time PCR (RTQ-TRAP) assay
Authors: Inna L. Botchkina, Rebecca Rowehl, Galina I. Botchkina
Journal: Cancer Research (2004)

994  Telomerase has a high potential as a biomarker of cancer, since its activity was demonstrated in about 90% of human cancers and all immortal cells, and in contrast, it is absent from most normal somatic tissues after birth. However, telomerase is activited not only during tumorigenesis in vivo and immortalization in vitro, but also in germ line, stem cells and some normal somatic cells with high proliferative potential. Although levels of telomerase activity (TA) in these cases were considered as low or undetectable by standard TRAP assays, the appearance of highly sensitive quantitative methods of detection, such as a real-time PCR, requires quantitative re-examination of telomerase status in human cell lines that are commonly used as a reference controls. Also, conflicting results were reported regarding cell cycle-dependent regulation of TA in normal and immortal cell lines. Materials and Methods. We used telomerase-positive prostate cancer, PC-3 cells line, and commonly referenced as telomerase-negative, IMR90 and HS27 cells (all cells were obtained from the SUNY Cell culture/hybridoma facility). PC-3 cells were cultured in F12K medium; IMR90 and HS27 cells were cultured in DMEM, supplemened with 10% fetal calf serum. All cells were cultured at 37° C under 5% CO2 in a humidified chamber. Quantitative real-time TRAP assay was carried out in a 96-well plate using the Opticon MJ Research instrument and optimized standard SYBR Green protocol for measurements of TA. For growth arrest in G2/M phase, subconfluent and confluent cells were treated with 0.5 μg/ml or 5 μg/ml of Nocodazole (Sigma) for 24 hours. For serum starvation of cells, a medium was supplemented with 0.5% FCS. For confluency experiments, cells were allowed to grow with one medium change after 5 days of culturing in specified medium supplemented with 10% FCS till full confluency, and after two weeks of growing, cells were treated with nocodazole as described. Results. Amplification plots revealed a cell number-dependent amplification of telomeric repeates on serial dilutions of all examined cell lines. Any nonspecific amplification was not occured since no difference in fluorescence signals in no template controls and at high degrees of sample dilution was detected. Highest telomerase activity was detected in PC-3 cells; both IMR90 and HS27 showed ∼10-20 times lower TA. For PC-3 cells, insignificant decrease in TA was seen after confluency was reached. Treatment with nocodazole further reduced TA in both subconfluent and confluent cells. In contrast, confluent IMR90 and HS27 cells had significantly lower TA compared to subconfluent ones. Nocodazole treatment reduced TA in subconfluent HS27 and IMR90 cells, and had no significant effect on TA levels in confluent cells.
FRI0621 Hospital admissions and readmissions in patients with rheumatoid arthritis. associated factors and direct health-care costs in a third level university hospital
Authors: J. E. Ruiz-Sará, N. Lozano-Rivas, P. Castillo Dayer, C. García-Belando, A. Paños-Iniesta, L. F. Linares, A. Bermudez, F. A. Martínez-Angosto, J. Martínez-Ferrín, M. J. Moreno, M. Castaño, P. Mesa del Castillo, F. García Gambín, F. Andrade Rodado, C. Marras-Fernández Cid
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> In last years, the direct health-care costs derived from admissions and readmissions to Rheumatology departments of patients with Rheumatoid Arthritis (RA) have diminished. Presumably, the higher survival rate and the amount of comorbidities of these patients have derived in an increased of admissions and direct costs to other medical and surgical departments. <h3>Objectives:</h3> To describe the admission and readmission causes of all patients with RA admitted during 2015 and 2016 and to identify factors associated to readmission. Finally to estimate the costs derived from these events in the same period. <h3>Methods:</h3> All electronic medical reports were revised; demographic, medical and therapeutic data, as well as diagnosis at discharge were collected. A descriptive analysis followed by a logistic regression analysis were done to identify readmission-associated variables. Financial analysis was done by calculating the price of the stay according to established in 2015-scale. <h3>Results:</h3> 240 admissions of 158 patients were found. Mean age 63,8 years, 69% women and mean evolution of RA of 13,1 years. At admission, 53% were on oral steroids and 45% with synthetic DMARD. Admissions were mainly distributed in Internal Medicine department (26%). Infections were the most frequent admission cause (33%), followed by cardiovascular events (20%) and oncological processes (13%). Forty-nine patients (31%) were readmitted, 47% due to infections. Age (OR/year 1.02 CI 95% 1.00–1.04), diabetes (OR 2.1 CI 95% 1.1–4.4) and chronic kidney disease (OR 3.3 CI 95% 1.0–10.2) were the associated risk factors. There were a total of 2172 days of stay with an estimated cost of 530420 euros and 783 days of stay due to readmissions with a total cost of 203218 euros. Departments which generated more costs either for admissions or readmissions were Oncology (65064 euros/19585 euros respectively) and Intensive Care (68011 euros/42651 respectively). Costs for admission and readmission in Rheumatology department were 5230 and 3175 euros respectively. <h3>Conclusions:</h3> Admission and readmission of patients with RA are mostly due to infections and cardiovascular causes. Estimated direct costs are higher for patients admitted to Intensive Care Unit or Oncology <h3>Disclosure of Interest:</h3> None declared
Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome
Authors: Ana Villalba, Leonor Senent, Esther Alonso, Elvira Mora, Teresa Bernal Del Castillo, Fernando Ramos, Arenillas Leonor, Ana Vicente, Teresa Orero, Mar Tormo, Teresa Ardanaz, Victor Marco, Maria Díez-Campelo, Andres Jerez, Julia Montoro, Beatriz Arrizabalaga, Rafael Lluch, Raquel de Paz, Patricia Font, Ignacio Lorenzo, Guillermo Sanz
Journal: Blood (2018)
MR guided high intensity focused ultrasound (MRgFUS) for the treatment of oligometastatic prostate cancer bone metastasis.
Authors: Alessandro Napoli, Luca Marchetti, Enrico Cortesi, Paolo Marchetti
Journal: Journal of Clinical Oncology (2020)

e17600 Background: With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Our aim was to determine MRgFUS ability to downstage patients with oligometastatic bone disease with single session of non-invasive metastasis-directed therapy. Methods: The study was designed with intention-to-treat metastatic bone lesions. Patients were enrolled if they had accessible bone metastasis and could safely undergo MRgFUS (InSightec, Israel). Baseline measurable characteristics included dynamic contrast enhanced MRI study (DCE; Gd-BOPTA, Bracco; GE 750 3T magnet) with semiquantitative perfusion analysis, PSA level (ng/ml) and choline PET (SUV). Measurable variables were obtained at treatment time, 3 months, 12 months and 24 months follow-up. Results: 18 patients fulfilled the inclusion criteria and safely underwent MRgFUS procedure of metastatic bone ablations. Lesions were located in the pelvis (11), scapula (3) and long bones (4). At baseline all lesions showed a significant DCE perfusion (highly vascular) with mean perfusion reduction of 88% at 3 months follow-up (CI: 100-50; p &lt; 0.001) stable at subsequent follow-up scans. Similarly PSA levels decreased from a mean baseline of 19 (ng/ml) to 7.1, 2.9 and 2.1, at 3-12 and 24 moths respectively. SUV values showed similar trend with reduction from baseline (mean 8.9 to 3.0, 2.3 and 1.7: p &lt; 0.001). In all patients single MRgFUS session was appropriate without any major or minor adverse events reported. Conclusions: MRgFUS is a totally non-invasive procedure that can obtain complete bone ablation in patients with oligometastatic prostate disease. The technique features a radiation-free approach that can be of incremental value in long-survivor subset on oncological patients, significantly reducing risk of toxic effects. Concurrent chemo regimen is not a contraindication.
THU0601 Carrier rate of familial mediterranean gene (MEFV) mutation in parents of children with familial mediterranean fever
Authors: V. Ziaee, Y. Aghighi, L. Shahbaznejad, S.-R. Raeeskarami, F. Tahghighi, A. Shakoori, H.R. Ajeedeh
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Familial Mediterranean Fever (FMF) is one of the most prevalent periodic fever syndromes, MEFV, the responsible gene for the disease is in the short arm of chromosome16. In the considerable count of the FMF patients, only one mutation is found in the MEFV, and parents who was the obligatory carriers for that mutation, were asymptomatic. <h3>Objectives</h3> The aim of this study was to evaluate these asymptomatic parents in regard to mutation in MEFV gene and similarity between parents and offspring patients. <h3>Methods</h3> In this cross sectional study, asymptomatic parents of FMF patients enrolled the study, which were referred to periodic fever clinic or paediatric rheumatology clinic of Tehran University of medical sciences. The patients should have at least one mutation in MEFV gene and none of them had any family history of auto inflammatory disease. Twelve mutations in MEFV gene was assessed in the parents by Vienna Lab FMF Strip Assay kit by MAS PCR/Reveres hybridization. <h3>Results</h3> Forty three patients and their parents participated in the study. Sixty three percent<sup>27</sup> of patients were male. Onset of disease symptoms in 31 patients (72%) were before 4 years of old. Nine (21%) of the patients were homozygote, 16 (37%) compound heterozygote and 17 (40%) heterozygote for MEFV mutation, there was a case of complex alleles mutations (2%). M694V/M694V in 4 patients (9%) was the most homozygote genotype, M694V/R761H in 4 (9%) and E148Q in 7 (16%) were the most compound heterozygote and heterozygote genotype, respectively. M694V, M680I and E148Q were the most mutation in the parents. Overall, 41 patients, had mutations similar to their parents' mutation, except in 2, which parents had not mutation, but patient did. <h3>Conclusions</h3> It seems that occurrence of new mutations in offspring is not prevalent among FMF patients, and there are other reasons for different clinical presentation in similar mutation carriers. On the other hand, in ethnicities with high prevalence of FMF, new mutation in descendant may occurs, infrequently. <h3>Acknowledgements</h3> This research was part of a Fellowship thesis (of Dr. L. Shahbaznejad) and it was approved and financially supported by a grant from Tehran University of Medical Sciences (No: 93–11–46–5001). The authors would like to thank parents who participated in the study. <h3>Disclosure of Interest</h3> None declared
Near‐Infrared‐Light Activatable Nanoparticles for Deep‐Tissue‐Penetrating Wireless Optogenetics
Authors: Nuo Yu, Ling Huang, Yubin Zhou, Tian Xue, Zhigang Chen, Gang Han
Journal: Advanced Healthcare Materials (2019)

Abstract Optogenetics has been developed to control the activities and functions of cells with high spatiotemporal resolution, cell‐type specificity, and flexibility. However, current optogenetic tools generally rely on visible light (e.g., blue or yellow) with shallow tissue penetration ability that does require invasive fiber‐optic probes to deliver visible light into organs and animal tissues. This often results in a series of side effects, such as tissue damage and unwanted inflammation. Fortunately, the emerging wireless optogenetic tools that can respond to deep‐tissue‐penetrating near‐infrared (NIR) light have attracted increasing attention due to their much‐reduced damage to living organisms. There are mainly two types of NIR‐activatable optogenetic tools: one uses lanthanide‐doped upconversion nanoparticles to transduce NIR light to visible light to modulate classical opsin‐expressing neurons; the other type couples with an NIR absorber to convert NIR light to heat to activate thermosensitive proteins. These NIR‐activatable optogenetic tools enable low‐invasive “remote control” activation and inhibition of cellular signaling pathways. This approach has great potential to help create more innovative therapies for diseases like cancer, diabetes, and neuronal disorders in the near future. Therefore, this review article summarizes the recent advances on design strategies and synthetic methods of NIR‐activatable nanomaterials for wireless optogenetic applications.
SAT0672 Is ultrasound remission achievable in patients with early rheumatoid arthritis?
Authors: T. Serban, I. Azzolin, I. Satulu, C.M. Mihai, G. Massazza, M. Bojinca, A. Iagnocco
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In rheumatoid arthritis (RA) the "window of opportunity" has a crucial role for better long-term outcomes.<sup>1</sup> The ACR/EULAR remission criteria for RA are mostly represented by clinical parameters, while ultrasound (US) is not included.<sup>2</sup> However, in early diagnosed and early treated patients, who fulfil the remission criteria, residual US modifications can be identified.<sup>3</sup> <h3>Objectives</h3> The aim of this study was to investigate whether significant US-detectable differences between early RA (ERA) patients treated for one year and healthy controls (HC) are present. <h3>Methods</h3> We enrolled in this cross-sectional study consecutive patients with ERA at 1 year after having initiated RA disease-modifying (DMARD) therapy and who had received treatment following RA recommendations. Only patients who had fulfilled EULAR/ACR 2010 criteria for RA<sup>4</sup> and with symptoms duration of less than 1 year at treatment initiation were included. US exams were performed in 10 joints bilaterally (wrist, MCP II-V) by using both gray-scale and Doppler for evaluating synovitis was graded according to a semi-quantitative 4-point scale (0–3). A total US score for synovitis was calculated by adding the values recorded at each joint site. The presence of erosions was also recorded. Finally, US results obtained in patients were compared to those detected in HC. <h3>Results</h3> 84 subjects were enrolled – 45 ERA patients and 39 HC. In ERA patients the mean duration of symptoms prior to diagnosis was 3.5±3.5 months. The demographic, clinical and US data are reported in table 1. <h3>Conclusions</h3> Patients with RA, who had been early diagnosed and early treated, after 1 year of tight control had still US inflammatory and erosive changes compared to HC. US assessment gives an added value to clinical evaluation in ERA, for its capacity to detect residual inflammatory abnormalities, even under optimised treatment and consequent structural lesions. <h3>References</h3> [1] van Nies JAB, et al. Ann Rheum Dis2015;74:806–812. [2] Bykerk VP1, Massarotti EM. Rheumatology2012;51(Suppl 6):vi16–20. [3] Vergara F, et al. Reumatol Clin2017Mar 18. [4] Aletaha D, et al. Arhritis Rheum2010;62:2569–2581. <h3>Disclosure of Interest</h3> None declared